Cutaneous mucormycosis by Castrejón Pérez, Ana Daniela et al.
Continuing mediCAl eduCAtion
Cutaneous mucormycosis*
Ana	Daniela	Castrejón-Pérez1	 Esperanza	C.	Welsh1
Ivett Miranda1 Jorge Ocampo-Candiani1
Oliverio Welsh1
 
DOI: http://dx.doi.org/10.1590/abd1806-4841.20176614
Abstract: Cutaneous mucormycosis is an emerging fungal infection caused by opportunistic fungi of the phylum Glomero-
mycota.	It	is	frequent	in	poorly	controlled	diabetic	patients	and	individuals	with	immunosuppression.	It	is	usually	acquired	
by	direct	inoculation	through	trauma.	The	clinical	presentation	is	nonspecific,	but	an	indurated	plaque	that	rapidly	evolves	to	
necrosis	is	a	common	finding.	Diagnosis	should	be	confirmed	by	demonstration	of	the	etiological	agent	and	new	molecular	
diagnostic	tools	have	recently	been	described.	It	is	an	invasive	life-threatening	disease	and	in	order	to	improve	survival,	a	
prompt	diagnosis	and	multidisciplinary	management	should	be	provided.	The	treatment	of	choice	is	amphotericin	B,	but	new	
azoles,	such	as	posaconazole	and	isavuconazole,	must	be	considered.	
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INTRODUCTION
Mucormycosis is an invasive fungal infection caused by op-
portunistic	fungi	of	the	phylum	Glomeromycota,	subphylum	Mu-
cormycotina. It usually affects poorly controlled diabetic patients 
and	individuals	with	immunosuppression.	Frequent	clinical	presen-
tations	include	rhinocerebral,	pulmonary	and	cutaneous	forms,	and	
less	 frequently,	 gastrointestinal,	 disseminated,	 and	 miscellaneous	
forms. This review will focus on cutaneous mucormycosis.
EPIDEMIOLOGY
In	developed	countries,	patients	with	allogeneic	hematopoi-
etic stem cell transplantations and other hematologic malignancies 
frequently	present	mucormycosis.1-3 In	contrast,	in	developing	coun-
tries,	uncontrolled	diabetes	mellitus	is	the	main	associated	disease.4
Its	global	incidence	is	unknown;	however,	in	Spain	the	in-
cidence	was	0.43	cases	per	million	per	year	in	2005.	In	France,	be-
tween	1997	and	2006,	an	increase	from	0.7	to	1.2	cases	per	million	
was	found,	mainly	in	patients	with	hematologic	malignancies	and	
bone marrow transplantation.1In	the	United	States	of	America,	there	
are no extensive prospective reports. In reports from the state of Cal-
ifornia,	incidence	was	1.7	cases	per	million	per	year.5
Zygomycetes	are	ubiquitous	in	nature	and	are	usually	iso-
lated	from	decaying	organic	matter,	soil,	wood,	cotton,	bread,	fruits,	
vegetables,	and	animal	excreta.3,6	Primary cutaneous mucormycosis 
is	often	acquired	by	direct	inoculation,	contaminated	dressings,	sur-
gery,	burns,	motor	vehicle	accidents,	and	insulin	injection	sites.1,7,8	
There are reports of outbreaks of mucormycosis in healthcare cen-
ters	due	to	contaminated	adhesive	tape,	wooden	tongue	depressors,	
ostomy	 bags,	 and	 building	 construction	 contamination.	Other	 re-
ports have associated this fungus with vascular devices and nitro-
glycerine patches.7,	9-11	In a review of 196 cases of healthcare-associat-
ed	mucormycosis,	57%	involved	the	skin.	Predominant	populations	
were	 premature	 infants,	 surgical	 patients,	 and	 immunocompro-
mised hosts.9
According	 to	 the	 largest	 review	of	reported	cases,	 the	age	
of presentation ranges from months to 87 years with a mean of 38 
years.	It	is	more	frequent	in	men	with	a	ratio	of	1.1:1.1,	2-12
The	classic	major	risk	factors	are	uncontrolled	diabetes	and	
ketoacidosis,	but	more	recently,	hematological	malignances	and	al-
logenic hematopoietic stem cell transplantation have become more 
frequent.	Other	underlying	conditions	are	solid	organ	transplanta-
tion,	deferoxamine	therapy,	drug	injections,	renal	failure,	infant	low	
birth	weight,	malnutrition,	HIV	infection,	systemic	lupus	erythema-
tosus,	burns,	trauma,	aplastic	anemia,	and	steroid	use.	1,2,7
Mucormycosis can also occur in patients with no predispos-
ing	factors.	According	to	Roden	et al,1in	50%	of	cases	of	cutaneous	
mucormycosis,	there	is	no	underlying	condition;	in	another	review,	
40%	of	patients	were	immunocompetent.7
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ETIOPATHOGENESIS
The	fungi	responsible	for	mucormycosis,	also	called	zygo-
mycosis,	were	previously	classified	in	the	class	Zygomycetes,	order	
Mucorales.	Zygomycetes	also	include	the	order	Entomophthorales,	
which	are	responsible	for	entomophthoramycosis.	Recently,	molec-
ular	phylogenetic	analyses	have	found	that	Zygomycota	are	poly-
phyletic,	and	these	fungi	have	been	placed	in	the	new	monophyletic	
phylum	called	Glomeromycota,	with	 the	 subphyliums	Mucormy-
cotina	and	Entomopthoromycotina.	In	this	context,	the	names	“mu-
cormycosis’’	 and	 ‘‘entomophthoramycosis”	 should	 be	 preferred,	
and	zygomycosis	should	be	dismissed.13
Most clinical isolates belong to the genera Rhizopus. In 
reviews	 of	 cutaneous	 mucormycosis,	 the	 most	 frequent	 isolated	
strains are Rhizopus oryzae,	Lichtheimia corymbifera and Apophysomy-
ces elegans. Other isolates reported are Mucor sp, Saksenaea vasiformis, 
Cunninghamella bertholletiae, Rhizomucor spp, and Rhizopus microspo-
rus.6,	 7-14	 In	Mexico,	 there	 is	 a	 case	 report	 of	 a	 new	 species	 called	
Apophysomyces mexicanus.15
CLINICAL ASPECTS
Cutaneous	mucormicosis	can	be	classified	as	primary	and	
secondary.	In	primary	disease,	the	skin	is	infected	by	direct	inocula-
tion	and	in	secondary	form,	by	dissemination	from	other	locations,	
more commonly from a rhinocerebral infection.3 It can be subcat-
egorized	 according	 to	 the	 pattern	 of	 infection	 as	 localized,	 deep,	
or	 disseminated.	 In	 a	 review	of	 929	 cases,	 176	patients	 presented	
with	 skin	 involvement.	Most	of	 these	 cases	 remained	 localized	 to	
the	total	depth	of	the	skin,	with	24%	showing	extension	to	bone	or	
muscle,	and	20%	developing	hematogenous	dissemination	to	other	
noncontiguous organs.1
The most affected areas of the skin are the arms and legs. 
Other	 locations	 include	 the	 scalp,	 face,	 thorax,	 back,	 abdomen,	
perineum, breast, neck and gluteal area.	7,10,16,17
Primary cutaneous mucormycosis may be gradual in onset 
or	 fulminant.	The	clinical	presentation	varies.	 Initially,	 lesions	are	
indurated	plaques	that	are	erythematous	to	purple.	These	become	
necrotic with an erythematous halo that can develop into an eschar.3,	
14 Other	presentations	include	targetoid	lesions, tender	nodules, ul-
cers, purpuric	lesions, and	swollen	and	scaly	plaques	(Figures	1	and	
2).8,18-24	In patients with surgical wound infections and burns it often 
appears as cellulitis and necrosis.10,25
In	 nosocomial	 infections,	 erythema	 and	 tenderness	 that	
rapidly	evolves	to	necrosis	is	often	found.	In	some	cases,	cutaneous	
lesions	resemble	contact	dermatitis,	which	progresses	to	ulceration	
with necrosis or necrotic exophytic tissue.11 The	presence	of	a	fistu-
lous tract from skin to liver allograft has been reported.26
Primary cutaneous mucormycosis by R. variabilis in inmu-
nocompetent hosts was reported in China and Japan. Unlike other 
mucorales,	these	presented	as	chronic	infections.27 These skin lesions 
were	infiltrated	plaques,	ulcers	and	nodules,	which	usually	remained	
localized	and	gradually	expanded	over	months	and	years.21-23
Secondary cutaneous mucormycosis usually results from a 
rhinocerebral	or	disseminated	infection	and	is	more	frequent	than	
primary disease. It has an acute onset and a high mortality. The 
disease usually starts as sinusitis and the most common cutaneous 
finding	is	a	necrotic	eschar	(Figures	3	and	4).3,28	The patients can also 
have	oral	involvement	with	necrotic,	black	or	white	ulcers	(Figure	
5).	 Other	 signs	 are	 fever,	 periorbital	 cellulitis,	 periorbital	 edema,	
ophthalmoplegia,	proptosis,	 loss	of	vision,	and	other	neurological	
deficits.29,30	The disease can be divided into three clinical stages: 
stage	 I,	 with	 signs	 and	 symptoms	 limited	 to	 the	 sino-nasal	 area;	
stage	II,	which	is	characterized	by	a	sino-orbital	infection;	and	stage	
III,	which	has	intracranial	involvement.30
FIgure 1: Cutaneous lesion of mucormycosis
FIgure 2: Cutaneous lesion of mucormycosis
FIgure 3: Ulceration with necrotic tissue in the 
eyelid with involvement of the eye
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DIFFERENTIAL DIAGNOSIS 
Primary cutaneous mucormycosis should be differentiated 
from aspergillosis and synergistic gangrene caused by bacterial in-
fections.	When	targetoid	 lesions	appear,	 the	differential	diagnoses	
include	autoimmune	disorders,	drug	reactions,	 infections,	 infiltra-
tive	diseases,	and	neoplastic	disorders.	In	some	cases,	it	can	mimic	
tinea corporis or pyoderma gangrenosum.3,18,31
In secondary mucormycosis with rhinocerebral involve-
ment,	 the	 differential	 diagnoses	 include	 centrofacial	 lymphomas,	
rhinoscleromas,	sinusitis,	anaerobic	infection,	and	aspergillosis.3
DIAGNOSIS
The	clinical	findings	of	cutaneous	mucormycosis	are	non-
specific.	Early	 identification	of	 the	 fungus	 is	 essential	 to	 establish	
prompt antifungal treatment. Early detection can be achieved by 
direct	 KOH	 microscopic	 examination,	 observing	 the	 presence	 of	
non-septated,	hyaline,	hyphae,	5μm wide and 20 to 50μm	long,	with	
irregular	branching	at	right	angles,	mainly	at	the	periphery	of	the	le-
sion. Impression smears from the wound edges may also be useful.3
Fungal	cultures	are	positive	 in	50%	of	cases,	but	 in	recent	
reviews there has been a clear increase in culture positivity from 
72%	to	89%	in	cutaneous	locations.1	6,7	Cultures must be performed 
in	Sabouraud	and	potato	dextrose	agar	media,	avoiding	media	with	
antibiotics that inhibit fungus growth.3
A	 biopsy	 and	 molecular	 diagnostic	 tests	 should	 be	 per-
formed.	The	biopsy	should	be	taken	from	the	center	of	the	lesion,	
including subcutaneous fat. Histology is more useful in primary 
cutaneous	mucormycosis.	Common	findings	are	edema,	thrombo-
sis,	infarctions,	necrosis	and	an	inflammatory	reaction	that	includes	
polymorphonuclear	 cells,	 plasma	 cells,	 and	 eosinophils.	 Thick,	
hyaline,	nonseptated	and	bifurcated	hyphae	may	be	seen	with	he-
matoxylin	and	eosin	stain	but	are	best	visualized	with	periodic	ac-
id-Schiff	 and	Grocott	 (Figure	 6).	Most	of	 the	microscopic	 features	
are	nonspecific	and	a	differential	diagnosis	with	other	filamentous	
fungi must be entertained.3,6
New molecular diagnostic tools have been developed to 
provide	precise	identification	of	the	fungus.	Still,	this	technology	is	
not available for most patients. These tests target the 18S ribosomal 
DNA	and	are	highly	specific	with	no	cross-reactivity	with	other	fil-
amentous fungi.32-35
Real-time	PCR	provides	identification	of	Mucorales in tissue 
samples	 and	 clinical	 isolates	 with	 high	 specificity.	 Nevertheless,	
more	sensitivity	has	been	reported	in	fresh	frozen	specimens	than	
in	formalin-fixed	paraffin-embedded	tissues.36,37	Bernal-Martinez	et 
al.38 developed a single tube multiplex real-time PCR to detect the 
genus Mucor, R. oryzae and R. microsporus from clinical and culture 
isolates.	This	method	has	100%	specificity,	and	provides	results	in	2	
to	3	hours.	Other	techniques	described	are	real-time	PCR	followed	
by	high	resolution	meta-analysis	and	rolling	circle	amplification	for	
the	ITS	region	of	ribosomal	DNA.34,39	However,	most	of	the	studies	
are retrospective and with small samples.
TREATMENT
A	multidisciplinary	approach	is	necessary	to	improve	sur-
vival in cutaneous mucormycosis. This should include extensive 
surgical	debridement,	antifungal	 therapy,	correction	of	 the	under-
lying	metabolic	or	 impaired	 immunological	 status,	and	control	of	
other	concomitant	infections	(Table	1).
The antifungal of choice is deoxycolate amphotericin B 
(d-AmB);	however,	it	is	often	substituted	by	lipid	formulations	be-
FIgure 4: Necrotic eschar and edema of the right eyelid
FIgure 5: Ulceration of the soft palate
FIgure 6: Skin	biopsy	that	shows	hyphae	(Hematoxylin	&	eosin,	X40)
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cause	of	their	better	safety	profile.40 They are also less nephrotoxic 
allowing longer treatment periods with higher doses. Some stud-
ies	have	shown	that	amphotericin	B	(AmB)	is	the	most	active	drug	
against	 mucorales	 clinical	 isolates,	 revealing	 MICs	 of	 <1 µg/mL 
in	the	majority	of	the	tested	strains.41 In immunocompromised pa-
tients,	the	recommended	doses	for	d-AmB	are	1-1.5mg/kg/day,	for	
liposomal	amphotericin	B	 (L-AmB),	 5-10mg/kg/day,	 and	 for	 am-
photericin B lipid complex 5 mg/kg/day. Increasing the dose does 
not achieve higher plasma levels. In order to increase the survival 
rate,	treatment	must	be	started	in	the	first	5	days	after	clinical	diag-
nosis. Improvement of comorbidities is imperative.26,	42	The duration 
of	 therapy	 is	 unclear.	 Some	 authors	 recommend	 continuing	AmB	
until	clinical	and	radiological	resolution,	others	recommend	6	to	8	
weeks.42,	43	Sometimes	this	is	not	possible	because	of	intolerance,	of-
ten secondary to renal failure.
Azole	 derivatives	 have	 exhibited	 variable	 activity	 against	
Mucorales in susceptibility in vitro	essays.	Posaconazole,	followed	
by	isavuconazole,	is	the	most	active;	itraconazole	has	limited	activi-
ty,	and	voriconazole	is	not	active.41,44-46
Posaconazole	has	been	described	as	second-line	therapy	in	
mucormycosis.47,48	Several retrospective studies with this antifungal 
drug	have	reported	good	results.	Mostly,	this	triazole	was	used	in	
patients	with	failure	or	intolerance	to	AmB.	The	advantages	of	the	
oral formulation is that it allows earlier patient discharge and de-
creases relapse with prolonged administration.49,50	In a single pro-
spective	study	of	21	patients	refractory	or	intolerant	to	AmB,	a	good	
response	was	reported	with	posaconazole,	with	the	exception	of	pa-
tients with disseminated disease.51 Posaconazole	is	recommended	as	
second-line treatment for patients with refractory disease or intol-
erance	to	AmB	or	for	those	who	need	prolonged	treatment	mainte-
nance.	The	suggested	dose	is	400mg	bid,	and	in	most	reported	cases	
therapy is provided for several months.52
Isavuconazole	is	a	new	azole	recently	approved	for	treatment	
of invasive mucormycosis in the United States.53 It	has	a	safety	profile	
similar	to	fluconazole	with	IV	and	oral	formulations	available.54 There 
are three reported cases of immunocompromised patients with pul-
monary,	rhinocerebral,	and	disseminated mucormycosis refractory to 
AmB	and	posaconazole	but	treated	successfully	with	isavuconazole.	
55-57 Recently	a	multicenter,	 clinical,	 single	arm,	open-label	 trial	was	
conducted,	including	34	patients	with	invasive	mucormycosis.	These	
patients	were	treated	with	isavuconazole	for	a	median	of	84	days.	At	
the	end	of	treatment,	5	patients	presented		complete	response,	6,	par-
tial	 response,	 10,	 stable	disease,	 and	15,	disease	progression.	There	
was	an	analysis	using	matched	historical	controls	treated	with	AmB	
that	 showed	no	difference	 in	mortality.	The	most	 frequent	 adverse	
event	were	gastrointestinal	symptoms,	but	less	than	10%	of	the	pa-
tients	presented	liver	enzyme	disturbances.58
Monotherapy	 with	 amphotericin	 is	 first-line	 treatment.	
There are reports and preclinical data on the use of combinations of 
different antifungals but there is a lack of clinical studies to support 
this	claim.	 If	necessary,	a	 lipid	 formulation	of	AmB	should	be	 the	
primary	antifungal,	combined	with	caspofungin	or	posaconazole.59
There	 is	a	 report	on	 the	use	of	 frozen	sections	 to	help	 the	
pathologist	 and	 surgeon	 define	 the	 final	 surgical	margins	 during	
surgical debridement of the affected tissue.60
PROGNOSIS
The overall mortality of all mucormycosis variants has im-
proved	from	84%	in	the	1950s	to	47%	in	the	1990s,	mostly	because	
of	treatment	with	AmB.	The	overall	mortality	of	cutaneous	mucor-
mycosis	 is	 less	 than	other	presentations	 of	mucormycosis,	 and	 in	
three	case	series	it	ranged	from	25%	to	31%.	In	localized	cutaneous	
mucormycosis,	mortality	ranged	from	4%	to	10%,	and	in	deep	ex-
tension	presentations,	it	ranged	from	26%	to	43%.	In	the	largest	case	
series,	the	mortality	rate	for	disseminated	disease	was	83%;1 howev-
er,	in	recent	reports	it	ranges	from	26%	to	50%.1,6,7
Roden et al.1 performed a multivariate regression analysis of 
risk	 factors	 for	mortality	 in	mucormycosis	and	found	some	signifi-
cant	mortality	risk	factors	that	included	disseminated	disease,	renal	
failure,	and	infection	due	to	Cunninghamella species. The use of anti-
fungal	therapy	and	surgical	treatment,	with	no	underlying	condition	
or	type	1	diabetes	mellitus	was	associated	with	a	significant	decrease	
in mortality.1,	 6,	 7	In	 the	experience	of	 a	Mexican	center,	where	most	
cases are associated to uncontrolled diabetes mellitus and metabolic 
acidosis,	the	mortality	rate	was	85%	in	patients	with	extensive	palpe-
bral disease and with a Glasgow Coma Scale lower than 6.3
CONCLUSIONS
Mucormycosis is an emerging invasive fungal disease that 
requires	a	high	level	of	clinical	skill	for	a	prompt	clinical	diagnosis	
Antifungal therapy                                        Non pharmacologic treatments
AmB	deoxycholate	 IV		 Standard	dose	0.25	-	0.75mg/kg/per	day
  Severe cases 1.0 - 1.5mg/kg/per day Control underlying conditions
   Surgery of sof`t tissue rhino-orbito-cerebral disease
Liposomal	AmB	 IV	 5	–	10mg/kg/	per	day	
AmB	Lipid	complex	 IV	 5	–	7.5mg/kg/	per	day	
Posaconazole	 PO	 400mg	bid	
Isavuconazole	 PO,	IV	 200mg	tid	for	6	doses,	then	200mg	qd	
Table 1: Treatment of mucormycosis
AmB, Amphotericin B; PO, by mouth; IV, intravenous
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in	order	to	improve	survival.	Where	available,	new	molecular	tests	
should be used to expedite diagnosis. First-line therapy is ampho-
tericin	B	combined	with	surgery;	second	generation	azoles	deriva-
tives can also be used. Controlling underlying conditions is also an 
important aspect of therapy. q
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Questions
s
1- In primary cutaneous mucormycosis the disease is most 
frequently acquired by:
 a.  Direct inoculation.
 b. Trauma.
 c. Contaminated dressings.
 d. Surgery.
2- Recently, in developed countries, an emerging risk fac-
tor for cutaneous mucormycosis is:
 a.		Allogenic	hematopoietic	stem	cell	transplantation.
 b. Diabetes Mellitus.
 c.	HIV	infection.
 d.	Aplastic	anemia.
3- Which is the most common species isolated in cutane-
ous mucormycosis?
 a. Rhizopus oryzae.
 b. Lichtheimia corymbifera.
 c. Apophysomyces elegans.
 d. Rhizopus microsporus.
4- In uncontrolled diabetic patients with secondary cuta-
neous mucormycosis it is frequent to find:
 a. Pulmonary mucormycosis.
 b. Rhinocerebral infection.
 c. Gastrointestinal disease.
 d. Miscellaneous mucormycosis. 
5- In China, an emerging form of chronic infection with an 
indolent course has been reported. The etiological agent 
related to this variety is:
 a. Rhizopus oryzae.
 b. Lichtheimia corymbifera.
 c. Apophysomyces elegans.
 d. Rhizomucor variabilis.
6- The targeted region of DNA used in molecular diagnos-
tic tools is:
 a.			Mitochondrial	DNA.
 b.	30S	ribosomal	DNA.	
 c. 18S	ribosomal	DNA.
 d. Gene encoding a ferulic acid esterase.
7- The in vitro tests have showed that the most active an-
tifungal is:
 a.			Isavuconazole.
 b.	Posaconazole.
 c. Caspofungin.
 d. Amphotercin	B.
8- Which of the following factors is not associated with a 
higher rate of mortality?
 a.   Disseminated disease.
 b. Steam cell receptor.
 c. Renal failure.
 d. Infection due to Cunninghamella species.
9- Which of the following factors is not associated with a 
significant increase in survival?
 a.   Use of antifungal therapy.
 b. Surgical treatment.
 c. Having no underlying condition.
 d. Use	of	filgastrim.
10- Which of the following antifungals has good in vitro 
activity?
 a.   Posaconazole.
 b. Echinocandins.
 c. Terbinafine.
 d.	Itraconazole.
11- In which group of patients is it uncommon to find mu-
cormycosis?
 a.   Premature infants.
 b. Surgical patients.
 c. Atopic	patients.
 d. HIV	patients.
12- In cutaneous primary mucormycosis, extension of the 
infection usually involves: 
 a.  	Only	superficial	skin.
 b. Total depth of the skin.
 c. Muscle extension.
 d. Bone extension.
13- What is the first clinical manifestation of rhinocerebral 
mucormycosis?
 a.   Sinusitis.
 b. Periorbital edema.
 c. Ophthalmoplejia.
 d. Proptosis. 
14- Which is the initial lesion of primary cutaneous mu-
cormycosis?
 a.   Targetoid lesions.
 b. Erythematous	plaque.
 c. Tender nodules.
 d. Ulcers.
15- Which is the main differential diagnosis of primary cu-
taneous mucormycosis?
 a.   Lymphoma.
 b. Rhinoscleroma.
 c. Drug reaction.
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 d. Aspergillosis.
16- Which is the clinical stage of a patient with mucormy-
cosis affecting the sino-orbital area?
 a.   Stage I.
 b. Stage II.
 c. Stage III.
 d.	Stage	IV.
17- What would you expect to observe in a direct KOH mi-
croscopic examination of the skin lesions?
 a.    Septated hyphae with acute angle or dichotomous 
branches.
 b.  Blastoconidial cells forming branched chains of pseudo-
hyphae.
 c. Thick-walled	spherules	filled	with	endospores.	
 d. Non-septated hyphae with right-angle branches.
18- Which of the following antifungals can be used as a 
strategy for early discharge of the patient?
 a.   Posaconazole.
 b.	Voriconazole.
 c. Terbinafine.
 d. Itraconazole.
19- Which phylum does mucormycosis fungus belong to? 
 a.  Chytridiomycota. 
 b. Glomeromycota.
 c. Neocllimastigomycota.
 d. Blastocladiomycota.
20- Which is the gold standard for diagnosing mucormy-
cosis?
 a.   PCR.
 b. Skin biopsy.
 c. Culture.
 d. KOH microscopic examination.
Answer key
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1.B
2.D
3.B
4.C
5.D
6.D
7.B
8.D
9.A
10.D
11.D
12.C
13.C
14.B
15.A
16.C
17.B
18.C
19.C
20.D
Papers
Information for all members:  The EMC-D questionnaire 
is now available at the homepage of the Brazilian Annals of 
Dermatology: www.anaisdedermatologia.org.br. The dead-
line for completing the questionnaire is 30 days from the date 
of online publication.
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